Nepitan 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older
- Usual administration in conjunction with other heart failure therapies
- Replacement of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains neprilysin inhibitor, sacubitril, and angiotensin receptor blocker, valsartan
- Inhibits neprilysin via LBQ657, the active metabolite of sacubitril
- Blocks the angiotensin II type-1 (AT1 ) receptor via valsartan
- Effects attributed to increased levels of peptides degraded by neprilysin and simultaneous inhibition of angiotensin II effects
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily
- Pediatric dose adjustment every 2 weeks, as tolerated by the patient
- Recommended dose titration for pediatric patients based on weight categories
Interaction
- Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Increased risk of lithium toxicity when used with lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors, aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- Starting dose adjustment required in patients with renal impairment
Precautions & Warnings
- May cause angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine and renal function
- Monitor serum potassium periodically and treat appropriately
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Dosage adjustment required in patients with severe renal impairment
- Dosage adjustment required in patients with moderate hepatic impairment
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available
- Hypotension is the most likely result of overdosage
- Symptomatic treatment should be provided
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children